Last updated: September 7, 2026
Cinacalcet hydrochloride has moved from a high-value branded calcimimetic to a mature generic medicine. Amgen’s Sensipar generated more than $1 billion annually at its peak, but U.S. patent expiry and generic entry sharply reduced branded revenue after 2018. The market remains clinically durable because cinacalcet is used in chronic kidney disease patients on dialysis, patients with parathyroid carcinoma, and selected patients with primary hyperparathyroidism. Price, procurement access, and formulation supply now drive competition more than clinical differentiation.
What is cinacalcet hydrochloride and how is it used?
Cinacalcet hydrochloride is an orally administered calcimimetic that increases the sensitivity of the calcium-sensing receptor to extracellular calcium. The mechanism reduces parathyroid hormone secretion and can lower serum calcium and phosphorus-related disease burden.
The U.S. Food and Drug Administration approved Sensipar in 2004. Its principal approved uses are:
| Indication |
Commercial relevance |
| Secondary hyperparathyroidism in adults with chronic kidney disease on dialysis |
Largest and most durable demand segment |
| Hypercalcemia in adults with parathyroid carcinoma |
Small patient population, high clinical need |
| Severe hypercalcemia in adults with primary hyperparathyroidism who cannot undergo parathyroidectomy |
Specialty indication with limited volume |
Cinacalcet does not replace dialysis, surgery, phosphate binders, or vitamin D analogs. It is used within a broader mineral-bone disorder treatment pathway.
How large is the cinacalcet hydrochloride market?
The market is mature, fragmented, and heavily genericized. Public company filings do not provide a consistent global market total because generic manufacturers generally report cinacalcet within broader product portfolios.
The market has three commercial tiers:
- U.S. branded and generic oral tablets.
- European and other international generic markets.
- Institutional and government procurement, where price competition is substantial.
Demand is relatively stable because the underlying dialysis population is recurring and treatment is chronic. Volume growth is tied to the global prevalence of end-stage kidney disease, dialysis access, nephrologist prescribing, and clinical preference for calcimimetic therapy.
The major commercial shift was from branded price control to generic tender and formulary competition. In the United States, this transition began after the expiry of Amgen’s core protection and the FDA’s approval of generic products.
What drives demand for cinacalcet?
Demand is supported by several structural factors:
- A growing global dialysis population.
- Long treatment duration among patients with secondary hyperparathyroidism.
- The need to control parathyroid hormone and calcium levels without surgery.
- Use in patients who cannot tolerate or do not respond adequately to vitamin D therapy.
- Hospital and dialysis-provider purchasing programs.
Demand is constrained by:
- Generic price erosion.
- Use of parathyroidectomy in suitable primary hyperparathyroidism patients.
- Intravenous calcimimetic competition from etelcalcetide.
- Treatment discontinuation caused by nausea, vomiting, or hypocalcemia.
- Reimbursement and formulary restrictions.
What were Sensipar’s peak sales and financial trajectory?
Sensipar was one of Amgen’s major established products before generic entry. Its financial trajectory followed a classic small-molecule lifecycle: rapid uptake, expansion into additional indications, peak sales, patent litigation, and abrupt post-expiry erosion.
| Period |
Financial development |
| 2004-2007 |
U.S. launch and expansion in secondary hyperparathyroidism |
| 2008-2013 |
International expansion and broader specialist adoption |
| 2014-2017 |
Mature branded product with high recurring revenue |
| 2018 |
Core U.S. exclusivity expired; generic competition began |
| 2019-2020 |
Rapid U.S. revenue decline and increased generic substitution |
| 2021 onward |
Sensipar became a legacy brand; generic products dominated U.S. volume |
Amgen reported Sensipar sales of approximately $1.5 billion in 2017 and approximately $1.7 billion in 2018, with the 2018 result benefiting from pre-generic purchasing and channel timing. Sales declined materially after generic competition emerged. Amgen’s reporting later grouped or reduced the visibility of Sensipar as it became less material to consolidated results. [1][2]
The key financial conclusion is that cinacalcet retained substantial unit demand after patent expiry, but the economic value shifted from the originator to generic manufacturers, distributors, and payers.
When did cinacalcet lose U.S. market exclusivity?
Cinacalcet’s practical U.S. exclusivity ended in 2018. The timing reflected the interaction of patent expiry, FDA approval of abbreviated new drug applications, litigation settlements, and any remaining regulatory exclusivity.
The first U.S. generic approvals were associated with Teva Pharmaceuticals and followed patent litigation involving Amgen. FDA approval enabled generic competition for the same principal tablet strengths and indications as Sensipar. [3]
The market should distinguish between three dates:
| Event |
Commercial impact |
| Patent expiry |
Removed the principal legal barrier to approval or launch |
| FDA ANDA approval |
Established regulatory authorization for a generic product |
| Commercial launch |
Created actual price and volume pressure |
For financial modeling, the commercial launch date is more important than the nominal patent expiration date. Generic manufacturers may delay launch because of settlement terms, supply arrangements, litigation risk, or market-entry strategy.
What patents protected Sensipar and cinacalcet hydrochloride?
Amgen’s principal U.S. cinacalcet estate was based on composition-of-matter and related claims covering calcimimetic compounds, including cinacalcet. The estate also included formulation and method-of-use protection.
Important historically litigated patents included:
| Patent |
General role in the estate |
Commercial outcome |
| U.S. Patent No. 6,011,068 |
Core cinacalcet compound and related chemical claims |
Expired after the branded protection period |
| U.S. Patent No. 6,211,244 |
Related calcimimetic compound claims |
Expired after the branded protection period |
| Later formulation and method claims |
Attempted to preserve protection around dosage forms and clinical use |
Less effective than composition protection against broad generic substitution |
The value of the estate was concentrated in the core active-ingredient protection. Once generic manufacturers could lawfully market cinacalcet tablets, formulation and method-of-use claims had limited ability to preserve the original branded market because the principal commercial product was an established oral tablet.
Patent expiry did not eliminate all litigation risk. Generic applicants could still face Paragraph IV litigation, induced-infringement allegations, or disputes over specific indications and formulations. The practical barrier, however, was substantially lower than before composition-of-matter expiry.
What Paragraph IV challenges affected cinacalcet?
Generic applicants used the abbreviated new drug application pathway and challenged listed patents under Paragraph IV of the Hatch-Waxman Act. Amgen brought patent litigation against generic applicants, including Teva and other manufacturers seeking to market cinacalcet tablets.
The litigation strategy had two commercial objectives:
- Delay or control generic launch.
- Preserve Sensipar revenue while negotiating market-entry terms.
The resulting settlements and approvals created a staged transition rather than an immediate simultaneous launch by every generic manufacturer. This structure affected generic timing, available supply, and early price erosion.
Paragraph IV risk was highest before the core patents expired. After expiry, litigation shifted toward product-specific claims, launch timing, and formulation or use claims rather than the basic right to market cinacalcet itself.
What is the FDA and Orange Book status of Sensipar?
Sensipar is an FDA-approved small-molecule drug. Its approved reference product is cinacalcet hydrochloride tablets marketed by Amgen.
The relevant regulatory characteristics are:
| Regulatory issue |
Status |
| FDA pathway |
New drug application for Sensipar; ANDA pathway for generics |
| Product type |
Small-molecule oral tablet |
| Reference product |
Sensipar |
| Biosimilar pathway |
Not applicable |
| Generic substitution |
Available through approved ANDA products |
| Orange Book relevance |
Listed patents and regulatory exclusivity governed historical generic timing |
Cinacalcet is not a biologic, so biosimilar competition is not relevant. Competitive entry occurs through generic-drug approval rather than the Public Health Service Act biosimilar pathway.
Orange Book protection for Sensipar was commercially important before generic approval. After the relevant patents expired and ANDA products entered the market, the Orange Book no longer supported the same level of branded market control. FDA Orange Book records remain the primary source for listed patent, exclusivity, dosage-form, and reference-product information. [4]
Which companies compete in the cinacalcet market?
The competitive field includes Amgen, generic pharmaceutical manufacturers, and providers of alternative calcimimetic therapy.
Generic manufacturers
U.S. and international generic competition has involved companies such as:
- Teva Pharmaceuticals
- Cipla
- Dr. Reddy’s Laboratories
- Sun Pharmaceutical Industries
- Amneal Pharmaceuticals
- Hikma Pharmaceuticals
- Other regional manufacturers and contract suppliers
The exact active supplier set varies by country, channel, and time. A manufacturer may hold FDA approval without maintaining meaningful commercial share.
Branded and alternative therapies
Etelcalcetide, marketed by Amgen as Parsabiv, is an intravenous calcimimetic administered in the dialysis setting. It competes with oral cinacalcet but has a different delivery model and may be easier to administer under dialysis-center supervision.
Other treatment alternatives include:
- Parathyroidectomy.
- Vitamin D receptor activators.
- Phosphate binders.
- Dialysis-based mineral-bone disorder management.
- Observation or medical management in selected primary hyperparathyroidism cases.
Cinacalcet retains advantages in oral administration and established clinical experience. Etelcalcetide has an adherence and administration advantage in dialysis centers but carries infusion-related and hypocalcemia considerations.
How does cinacalcet compare with etelcalcetide?
| Attribute |
Cinacalcet hydrochloride |
Etelcalcetide |
| Administration |
Oral tablet |
Intravenous administration after hemodialysis |
| Primary commercial use |
Chronic dialysis-related secondary hyperparathyroidism |
Dialysis-center calcimimetic therapy |
| Regulatory class |
Small-molecule drug |
Peptide drug |
| Generic or biosimilar exposure |
Generic competition |
No conventional biosimilar market equivalent in the same sense |
| Adherence profile |
Patient-dependent |
Provider-controlled |
| Price pressure |
High because of generic entry |
Greater branded protection historically |
| Supply model |
Retail, specialty, and institutional |
Dialysis-center procurement |
The two products can compete clinically, but they do not have identical commercial economics. Cinacalcet is exposed to generic substitution. Etelcalcetide is more dependent on dialysis-provider purchasing, administration economics, and Amgen’s continuing commercial strategy.
What formulation patents protect cinacalcet?
The commercial value of formulation patents is lower than the value of the original compound patents. Cinacalcet tablets contain a well-established active ingredient and do not require a complex delivery device, depot system, or biologic manufacturing process.
Potential formulation protection can cover:
- Tablet composition.
- Excipients.
- Manufacturing processes.
- Dissolution characteristics.
- Stability.
- Specific dosage strengths.
- Patient-use or administration schedules.
These claims may support targeted litigation but generally do not block all generic versions once the core active-ingredient protection has expired. Generic applicants can design around narrow formulation claims by using different excipients or manufacturing methods, subject to bioequivalence requirements.
Does cinacalcet have manufacturing or intellectual-property barriers?
Manufacturing barriers are moderate rather than severe. Cinacalcet is a synthetic small molecule, and generic production does not require cell culture, sterile fill-finish, or complex biologic characterization.
The main barriers are:
- Active pharmaceutical ingredient qualification.
- Control of impurities and polymorphic forms.
- Consistent tablet dissolution.
- Bioequivalence.
- Regulatory documentation.
- Reliable supply of active ingredient.
- Commercial scale and tender access.
Manufacturing know-how can create temporary advantages, particularly where regulatory authorities identify quality deficiencies or supply interruptions. It is not, however, equivalent to the manufacturing barriers associated with monoclonal antibodies, gene therapies, or complex inhaled products.
What generic launch risks exist for cinacalcet?
The largest generic launch risk is price compression. Once multiple approved suppliers compete, reimbursement contracts and pharmacy substitution can reduce net prices rapidly.
A generic manufacturer’s commercial outcome depends on:
| Risk factor |
Effect |
| Number of approved suppliers |
More suppliers generally increase price pressure |
| Contracting with dialysis providers |
Can determine high-volume access |
| API reliability |
Shortages can create temporary pricing power |
| Product recalls or quality findings |
Can shift share quickly |
| Wholesale and pharmacy coverage |
Determines retail substitution |
| State substitution rules |
Affect branded retention |
| Settlement restrictions |
Can delay or stage entry |
Generic revenue may remain attractive despite low unit prices because treatment is chronic and patient turnover is limited. The product is more likely to support a stable portfolio contribution than blockbuster-level profitability.
What litigation and settlement issues affected the market?
Amgen’s litigation against generic applicants was the central legal event in the U.S. cinacalcet market. The disputes focused on listed patents and generic applicants’ assertions that patents were invalid, unenforceable, or not infringed.
The litigation environment produced:
- Delayed or staged generic commercialization.
- Negotiated launch dates.
- Continued Sensipar sales during the pre-entry period.
- Reduced certainty around the exact timing of generic revenue erosion.
- A transition from one dominant brand to multiple generic suppliers.
Settlement agreements in pharmaceutical patent cases can include launch licenses, supply terms, authorized-generic arrangements, or restrictions tied to specific products. The economic effect can differ substantially from a simple “patent expiry equals immediate generic entry” model.
What is the outlook for cinacalcet revenue?
The outlook is stable in volume and weak in branded pricing.
Originator outlook
Sensipar has limited growth potential as a branded product. Its revenue exposure is concentrated in residual brand loyalty, supply continuity, and markets where generic penetration is incomplete. Amgen’s more important strategic exposure is the broader mineral-bone disorder portfolio, including Parsabiv, rather than the original Sensipar franchise.
Generic outlook
Generic manufacturers can expect:
- Recurring demand from dialysis patients.
- Lower prices than the branded product.
- Competition for pharmacy and dialysis-provider contracts.
- Periodic supply-driven price movements.
- Limited differentiation between approved tablet products.
Market outlook
The global market should remain clinically relevant because chronic kidney disease and dialysis demand persist. Financial growth will be constrained by genericization. The strongest commercial opportunities are likely to arise in markets with incomplete generic penetration, unreliable supply, or expanding dialysis infrastructure.
Key Takeaways
- Cinacalcet hydrochloride is a mature oral calcimimetic used mainly in dialysis-related secondary hyperparathyroidism.
- Amgen’s Sensipar reached approximately $1.5 billion to $1.7 billion in annual sales before U.S. generic competition.
- U.S. exclusivity ended in practical terms around 2018, after core patent expiry and FDA generic approvals.
- Teva and other generic manufacturers challenged Amgen’s patent estate under Paragraph IV procedures.
- The market is not exposed to biosimilar competition because cinacalcet is a small-molecule drug.
- Generic substitution has reduced branded revenue while preserving recurring treatment volume.
- Etelcalcetide is the principal branded calcimimetic comparator, but its intravenous dialysis-center model differs materially from oral cinacalcet.
- The remaining commercial barriers are mainly supply, quality, contracting, and regulatory execution rather than fundamental patent protection.
FAQs
Is cinacalcet hydrochloride still profitable for generic manufacturers?
Yes, but it is a volume-driven generic opportunity rather than a branded-style blockbuster. Profitability depends on supplier count, API cost, contracting, and access to dialysis-provider or pharmacy channels.
Is Sensipar still protected by patents?
The core U.S. patent protection that supported Sensipar’s exclusivity expired before broad generic commercialization. Later formulation or method claims may have had narrower relevance, but they did not preserve the original branded market.
Can a generic manufacturer launch cinacalcet for only one indication?
A generic may use labeling and regulatory strategies that address patent-protected indications, including section viii approaches where legally available. The commercial effect depends on the specific Orange Book listings, label, and litigation posture.
Does cinacalcet face competition from biosimilars?
No. Cinacalcet is a chemically synthesized small molecule. Competition occurs through ANDA-approved generics, not biosimilars.
What is the largest long-term risk to cinacalcet demand?
The largest risk is sustained price erosion combined with substitution by intravenous etelcalcetide, surgery, or other mineral-bone disorder treatments. Absolute volume is more resilient than revenue because dialysis-related use is chronic.
References
-
Amgen Inc. (2018). 2018 annual report. Amgen Inc.
-
Amgen Inc. (2019). 2019 annual report. Amgen Inc.
-
U.S. Food and Drug Administration. (2018). FDA approves first generic versions of Sensipar. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2004). FDA approves Sensipar for treatment of hyperparathyroidism in dialysis patients. U.S. Department of Health and Human Services.
